DeepMed Research

Corcept Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 352

Market Cap: $3.6B

Website

Clinical Trials

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-CORT125281

First Posted Date: 2019-03-18

Last Posted Date: 2019-03-18

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 6

Registration Number: NCT03877952

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Phase 1

Completed

Conditions: Antipsychotic-induced Weight Gain

Interventions: Drug: Olanzapine
Drug: Placebo
Drug: CORT118335

First Posted Date: 2019-03-15

Last Posted Date: 2020-04-28

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 96

Registration Number: NCT03877562

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Miricorilant
Drug: Placebo

First Posted Date: 2019-01-30

Last Posted Date: 2022-08-31

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 12

Registration Number: NCT03823703

Locations: 🇺🇸
Site 208, Glendale, Arizona, United States
🇺🇸
Site 234, Port Orange, Florida, United States
🇺🇸
Site 215, Edinburg, Texas, United States

and more 12 locations

This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.

Phase 2

Completed

Conditions: Antipsychotic-induced Weight Gain (AIWG)

Interventions: Drug: Miricorilant
Drug: Placebo

First Posted Date: 2019-01-28

Last Posted Date: 2023-02-08

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 71

Registration Number: NCT03818256

Locations: 🇺🇸
Site 239, Garden Grove, California, United States
🇺🇸
Site 143, Bentonville, Arkansas, United States
🇺🇸
Site 249, Little Rock, Arkansas, United States

and more 21 locations

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Cancer
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Relacorilant
Drug: Nab-paclitaxel

First Posted Date: 2018-12-17

Last Posted Date: 2025-04-30

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 178

Registration Number: NCT03776812

Locations: 🇧🇪
Site Reference ID/Investigator #108, Leuven, Belgium
🇪🇸
Site Reference ID/Investigator #114, Madrid, Spain
🇪🇸
Site Reference ID/Investigator #116, Madrid, Spain

and more 21 locations

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Phase 3

Completed

Conditions: Cushing Syndrome

Interventions: Drug: Relacorilant
Other: Placebo

First Posted Date: 2018-10-05

Last Posted Date: 2025-04-24

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 152

Registration Number: NCT03697109

Locations: 🇺🇸
Site 21, Phoenix, Arizona, United States
🇺🇸
Site 36, Los Angeles, California, United States
🇺🇸
Site 68, Torrance, California, United States

and more 61 locations

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Phase 2

Active, not recruiting

Conditions: Cushing Syndrome

Interventions: Drug: relacorilant

First Posted Date: 2018-07-27

Last Posted Date: 2025-05-02

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 125

Registration Number: NCT03604198

Locations: 🇺🇸
Site 7, El Paso, Texas, United States
🇪🇸
Site 38, Málaga, Spain
🇪🇸
Site 19, Sevilla, Spain

and more 46 locations

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relacorilant (3x100 mg softgel capsules)
Drug: Relacorilant (3x100 mg hard-shell capsules)
Drug: Relacorilant (6x50mg hard-shell capsules)

First Posted Date: 2018-05-30

Last Posted Date: 2018-09-07

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT03540836

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relacorilant 350mg
Drug: Itraconazole
Drug: Relacorilant 300mg

First Posted Date: 2018-04-30

Last Posted Date: 2020-03-24

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 52

Registration Number: NCT03512548

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Matching Placebo of CORT125134
Drug: CORT125134
Drug: Mifepristone
Drug: Prednisone
Drug: Glucose

First Posted Date: 2018-04-26

Last Posted Date: 2019-08-09

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 130

Registration Number: NCT03508635

Locations: 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy